Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

• Bladder
• Breast
• Gastrointestinal
• Head and Neck
• Leukemia
• Lung
• Lymphoma
• Pancreatic
• Prostate
• Solid Tumors

 

Bladder

• IMMU-132 for Metastatic Urothelial Cancer

  A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)
  

  ---

Breast

• Post-Mastectomy/Lumpectomy Radiation after Neoadjuvant Chemotherapy

  A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
  

  ---

Gastrointestinal

• Chemotherapy +/- Pembrolizumab in 1st Line Her2- Gastric or GEJ cancer

  A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
  

  ---

• Trastuzumab/Chemotherapy +/- Pembrolizumab in 1st Line Her2+ Gastric or GEJ Cancer

  A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
  

  ---

• Nivolumab +/- Ipilimumab with Fluorouracil plus Cisplatin in Esophageal Squamous Cell

  A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
  

  ---

Head and Neck

• Atezolizumab in Adjuvant Setting for Advanced Squamous Cell Carcinoma of the Head and Neck

  A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (anti PD-L1 antibody) as Adjuvant Therapy after definitive local therapy in patients with high risk locally advanced Squamous Cell Carcinoma of the Head and Neck
  

  ---

Leukemia

• Zanubrutinib vs. Ibrutinib for Relapsed/Refractory CLL/SLL

  A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  

  ---

• Azacitidine +/- Pevonedistat for High Risk MDS, CML, or Low-Blast AML

  A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
  

  ---

Lung

• Canakinumab for Adjuvant Non-Small Cell Lung Cancer

  A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer
  

  ---

Lymphoma

• Zanubrutinib for Marginal Zone Lymphoma

  A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma (BGB-3111-214)
  

  ---

• Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

  A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above
  

  ---

• Rituximab +/- Ibrutinib for Follicular Lymphoma

  A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
  

  ---

• TGR-1202 in patients with DLBCL, FL, SLL, or MZL

  A phase 2b randomized study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
  

  ---

Pancreatic

• FOLFIRINOX +/- CPI-613 in Pancreatic Cancer

  A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
  

  ---

• Tumor Treating Fields with Gemzar/Nab-Paclitaxel for Pancreatic Cancer

  Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
  

  ---

Prostate

• Enzalutamide +/- Pembrolizumab in Prostate Cancer

  A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  

  ---

• Radiation Trial for Immediate Risk Prostate Cancer

  Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (NRG-GU005)
  

  ---

Solid Tumors

• Cabozanitib +/- Atezolizumab in Solid Tumors

  A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
  

  ---

• AVID100 in Patients with Advanced or Metastatic Solid Tumors

  A phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100. an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin
  

  ---

• INCMGA00012 in Solid Tumors

  A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors
  

  ---

• Febrile Neutropenia Observational Trial

  A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN
  

  ---

• MGCD516 for Solid Tumor Malignancies

  A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
  

  ---